Drug intelligence / Profile preview

HUBPE007.1

Development stage: Preclinical
Lead developer: Ambiotech
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

HUBPE007.1 is an exosome-based therapy being developed by AM Biotech for the treatment of degenerative arthritis and for use as a bone medical device. The product is generated using the company's proprietary Biochemical Pulse Exosome Drug Development Platform, which aims to produce exosomes with specific therapeutic properties for tissue regeneration. In the context of orthopedic care, HUBPE007.1 is intended to facilitate bone repair and joint health. It is currently in the preclinical stage of development and is categorized as a medical device for its orthopedic indications.

Beyond the preview

Go deeper on HUBPE007.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUBPE007.1.

Explore the full profile